Drugs & Targets FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations September 20, 2024Vol.50 No.35
Drugs & Targets FDA approves Kisqali + aromatase inhibitor for early high-risk breast cancer September 20, 2024Vol.50 No.35
Drugs & Targets FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo September 20, 2024Vol.50 No.35
Drugs & Targets FDA issues draft guidance on conducting multiregional clinical trials in oncology September 20, 2024Vol.50 No.35
Drugs & Targets FDA issues guidance on implementing decentralized elements in clinical trials September 20, 2024Vol.50 No.35
Drugs & Targets FDA issues guidance on integrating randomized controlled trials into routine clinical practice September 20, 2024Vol.50 No.35
Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies September 13, 2024Vol.50 No.34By McKenzie Prillaman
Drugs & Targets FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy September 13, 2024Vol.50 No.34
Drugs & Targets FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas September 13, 2024Vol.50 No.34
Drugs & Targets FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee September 13, 2024Vol.50 No.34
